226 related articles for article (PubMed ID: 28440489)
1. Genome-wide DNA methylation sequencing reveals miR-663a is a novel epimutation candidate in CIMP-high endometrial cancer.
Yanokura M; Banno K; Adachi M; Aoki D; Abe K
Int J Oncol; 2017 Jun; 50(6):1934-1946. PubMed ID: 28440489
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer.
McInnes T; Zou D; Rao DS; Munro FM; Phillips VL; McCall JL; Black MA; Reeve AE; Guilford PJ
BMC Cancer; 2017 Mar; 17(1):228. PubMed ID: 28351398
[TBL] [Abstract][Full Text] [Related]
3. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
Kim JH; Bae JM; Cho NY; Kang GH
Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
[TBL] [Abstract][Full Text] [Related]
4. Status and significance of CpG island methylator phenotype in endometrial cancer.
Zhang QY; Yi DQ; Zhou L; Zhang DH; Zhou TM
Gynecol Obstet Invest; 2011; 72(3):183-91. PubMed ID: 21968189
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.
Levine AJ; Phipps AI; Baron JA; Buchanan DD; Ahnen DJ; Cohen SA; Lindor NM; Newcomb PA; Rosty C; Haile RW; Laird PW; Weisenberger DJ
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):68-75. PubMed ID: 26512054
[TBL] [Abstract][Full Text] [Related]
7. The Relationship between the Methylation of Promoter Regions of Tumor Suppressor Genes PTEN and APC with Endometrial Cancer.
Ghazanfari T; Asaadi Tehrani G; Maziri P
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2259-2265. PubMed ID: 31450893
[TBL] [Abstract][Full Text] [Related]
8. Clinical and prognosis value of the CIMP status combined with MLH1 or p16
Saadallah-Kallel A; Abdelmaksoud-Dammak R; Triki M; Charfi S; Khabir A; Sallemi-Boudawara T; Mokdad-Gargouri R
Med Oncol; 2017 Aug; 34(8):147. PubMed ID: 28730335
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic insights into colorectal cancer: comprehensive genome-wide DNA methylation profiling of 294 patients in Korea.
Joe S; Kim J; Lee JY; Jeon J; Byeon I; Han SW; Ryoo SB; Park KJ; Song SH; Cho S; Shim H; Bao Khanh Chu H; Kang J; Lee HS; Kim D; Kim YJ; Kim TY; Kim SY
BMB Rep; 2023 Oct; 56(10):563-568. PubMed ID: 37574809
[TBL] [Abstract][Full Text] [Related]
10. Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer.
Wong JJ; Hawkins NJ; Ward RL; Hitchins MP
Mod Pathol; 2011 Mar; 24(3):396-411. PubMed ID: 21102416
[TBL] [Abstract][Full Text] [Related]
11. CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci.
Kawasaki T; Ohnishi M; Nosho K; Suemoto Y; Kirkner GJ; Meyerhardt JA; Fuchs CS; Ogino S
Mod Pathol; 2008 Mar; 21(3):245-55. PubMed ID: 18204436
[TBL] [Abstract][Full Text] [Related]
12. Subsets of microsatellite-unstable colorectal cancers exhibit discordance between the CpG island methylator phenotype and MLH1 methylation status.
Kim JH; Rhee YY; Bae JM; Kwon HJ; Cho NY; Kim MJ; Kang GH
Mod Pathol; 2013 Jul; 26(7):1013-22. PubMed ID: 23370766
[TBL] [Abstract][Full Text] [Related]
13. Concerted promoter hypermethylation of hMLH1, p16INK4A, and E-cadherin in gastric carcinomas with microsatellite instability.
Kim H; Kim YH; Kim SE; Kim NG; Noh SH; Kim H
J Pathol; 2003 May; 200(1):23-31. PubMed ID: 12692837
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma.
An C; Choi IS; Yao JC; Worah S; Xie K; Mansfield PF; Ajani JA; Rashid A; Hamilton SR; Wu TT
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):656-63. PubMed ID: 15701853
[TBL] [Abstract][Full Text] [Related]
15. Unique DNA methylome profiles in CpG island methylator phenotype colon cancers.
Xu Y; Hu B; Choi AJ; Gopalan B; Lee BH; Kalady MF; Church JM; Ting AH
Genome Res; 2012 Feb; 22(2):283-91. PubMed ID: 21990380
[TBL] [Abstract][Full Text] [Related]
16. Genome-scale analysis of aberrant DNA methylation in colorectal cancer.
Hinoue T; Weisenberger DJ; Lange CP; Shen H; Byun HM; Van Den Berg D; Malik S; Pan F; Noushmehr H; van Dijk CM; Tollenaar RA; Laird PW
Genome Res; 2012 Feb; 22(2):271-82. PubMed ID: 21659424
[TBL] [Abstract][Full Text] [Related]
17. Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr virus-associated gastric carcinomas.
He D; Zhang YW; Zhang NN; Zhou L; Chen JN; Jiang Y; Shao CK
Med Oncol; 2015 Apr; 32(4):92. PubMed ID: 25720522
[TBL] [Abstract][Full Text] [Related]
18. CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma.
Jing F; Yuping W; Yong C; Jie L; Jun L; Xuanbing T; Lihua H
Tumour Biol; 2010 Aug; 31(4):321-31. PubMed ID: 20490964
[TBL] [Abstract][Full Text] [Related]
19. Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer.
Ichimura N; Shinjo K; An B; Shimizu Y; Yamao K; Ohka F; Katsushima K; Hatanaka A; Tojo M; Yamamoto E; Suzuki H; Ueda M; Kondo Y
Cancer Prev Res (Phila); 2015 Aug; 8(8):702-11. PubMed ID: 26063725
[TBL] [Abstract][Full Text] [Related]
20. Identification of endometrial cancer methylation features using combined methylation analysis methods.
Trimarchi MP; Yan P; Groden J; Bundschuh R; Goodfellow PJ
PLoS One; 2017; 12(3):e0173242. PubMed ID: 28278225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]